A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity,

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.

Oprah Winfrey admitted two years ago to taking diabetes medication to lose weight. Now, in a new podcast episode, she revealed that this process has helped her understand "thin" people. Oprah Winfrey has struggled with weight issues for years.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The media icon, 70, took to her podcast last week to share her experience with an undisclosed type of GLP-1 drug that she began taking in 2023.